tirzepatide for research purposes 5mg GIP/GLP-1 Receptor agonist Tirzepatide Peptide | Research Peptide

On medication type: The medications available through Gala GLP-1 are compounded - not FDA-approved finished drug products

This is to ensure we can help with dosing, self injecting, & aid in any side effects

Tirzepatide reduces appetite by activating two hormone pathways simultaneouslythe GLP-1 and GIP receptorsmaking it more potent than single-action medications

In vitro , GIP(17-30) and GIP(4-42) did not increase cellular cAMP production and had only weak insulin releasing activity compared with the native GIP (64)

The research on this is limited

These protective effects involve activation of cell survival pathways and may include antioxidant mechanisms, though the precise molecular pathways mediating cytoprotection require further elucidation